-
01:17:54 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

APDN Stock News

12/01/20 8:00 AM
Nasdaq : APDN
covid-19low float
Applied DNA to Provide COVID-19 Surveillance Testing to Stony Brook Basketball
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that its wholly-owned subsidiary, Applied DNA Clinical Laboratories, LLC (“ADCL”), will provide its COVID-19 surveillance testing program to the Stony Brook University Seawolves men’s and women’s basketball teams. ADCL’s pooled surveillance testing platform, known as safeCircle™, will aid the safe return to
RHEA-AI
neutral
11/30/20 7:00 AM
Nasdaq : APDN
clinical trialcovid-19low float
Applied DNA, EvviVax, and GVS Receive Regulatory Approval to Conduct Veterinary Clinical Trial for Linear COVID-19 Vaccine Candidate
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, EvviVax, S.R.L. (“EvviVax”), a spin-off of Takis Biotech with expertise in engineered veterinary cancer immunotherapy and targeted vaccines, and Veterinary Oncology Services at Guardian Veterinary Specialists (GVS), a multi-specialty veterinary hospital, announced the receipt of approvals from the New York State Depa
RHEA-AI
neutral
11/27/20 10:39 AM
Nasdaq : APDN
conferenceslow float
Applied DNA to Present at the Imperial Capital 2020 Security Investor Conference on December 3
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that it is scheduled to participate virtually in the Imperial Capital 2020 Security Investor Conference on Thursday, December 3, 2020. Dr. James A. Hayward, chief executive officer, will present at 10:45 a.m. EST that day and host one-on-one meetings throughout the day. An archived webcast will be available
RHEA-AI
neutral
11/25/20 8:00 AM
Nasdaq : APDN
covid-19low float
Applied DNA Significantly Expands Addressable Market for Linea™ COVID-19 Assay Kit via Successful Amendment to FDA EUA
Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that the U.S. Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) amendment that expands the installed base of RT-PCR platforms that can process the Company’s Linea™ COVID-19 Assay Kit. The EUA amendment extends the RT-PCR platform authorization from Applied Biosystems’ (Therm
RHEA-AI
neutral
11/12/20 8:00 AM
Nasdaq : APDN
covid-19low float
Applied DNA Secures Blanket Purchase Order for 10,000 Linea™ COVID-19 Tests
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it has secured a blanket purchase order from an existing customer for its Linea™ COVID-19 Assay Kit (the “Assay Kit”) and consumables to conduct 10,000 tests. The Company has already shipped a portion of the purchase order in the current fiscal quarter ending December 31, 2020. The balance of the
RHEA-AI
neutral
11/10/20 7:00 AM
Nasdaq : APDN
covid-19low float
Stony Brook University Hospital Launches COVID-19 Surveillance Testing Program Powered by Applied DNA’s Assay Kit and Services
Applied DNA Sciences, Inc., (NASDAQ: APDN) (“Applied DNA” or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its Linea™ COVID-19 Assay Kit (the “Assay Kit”) has been selected by Stony Brook University Hospital (SBUH) for use in SBUH’s newly launched COVID-19 surveillance testing program (the “Program”). At peak operations, the Program will utilize frequent pooled testing to enable the early detection an
RHEA-AI
neutral
10/30/20 8:00 AM
Nasdaq : APDN
covid-19low float
Applied DNA to Increase COVID-19 Surveillance Testing Utility for its Linea™ COVID-19 Assay Kits Through Expanded Use of Robotic Automation
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics in vitro, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting, and anti-theft technology, today announced that it plans to boost its COVID-19 testing capacity at Applied DNA Clinical Laboratories, LLC (“ADCL”), its wholly-owned subsidiary, to
RHEA-AI
positive
10/12/20 7:30 AM
Nasdaq : APDN
covid-19low float
Applied DNA Secures $1.0+ Million in COVID-19 Surveillance Testing Annualized Revenue, Builds Sales Pipeline for Test Kit and Testing-as-a-Service
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting, and anti-theft technology, announced that Applied DNA Clinical Laboratories, LLC (“ADCL”), its wholly-owned subsidiary, has secured COVID-19 surveillance testing contracts under i
RHEA-AI
positive
09/29/20 9:40 AM
Nasdaq : APDN
covid-19low float
Applied DNA Signs Master Services Agreement with Stony Brook University Hospital for COVID-19 Diagnostic Assay Kit and Automated Systems, Receives Initial Purchase Order
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced the signing of a Master Services Agreement (MSA) with Stony Brook University Hospital (“SBUH”), the largest academic medical center on Lo
RHEA-AI
neutral